Physician profile
William Cole
NPI 1205820701
$435.26
in general payments reported to CMS, 2019-2025
10 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $96.47 · 2024: $102 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $338.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $108.45 | 2024-2025 | Repatha, Repatha |
| Abbvie INC. | $74.77 | 2022 | |
| Novartis Pharmaceuticals Corporation | $46.72 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $45.04 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $40.68 | 2022-2025 | Verquvo |
| Pfizer INC. | $27.77 | 2024 | |
| Scpharmaceuticals INC. | $27.62 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.41 | 2025 | |
| Novo Nordisk INC | $22.03 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $19.77 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.